Overview Dividends

(ARCT) Arcturus Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03969T1097

Vaccine, mRNA, Liver, Respiratory, Rare

Biotechnology
Market Cap in USD: 178m
IPO / Inception: 2020-04-16
Return 12m vs S&P 500: -69.8%

EPS (Earnings per Share)

EPS (Earnings per Share) of ARCT over the last years for every Quarter: "2020-12": -1.25, "2021-03": -2.15, "2021-06": -2.07, "2021-09": -2.05, "2021-12": -1.47, "2022-03": -1.94, "2022-06": -0.82, "2022-09": -1.33, "2022-12": 4.43, "2023-03": 1.87, "2023-06": -1.98, "2023-09": -0.61, "2023-12": -0.32, "2024-03": -1, "2024-06": -0.64, "2024-09": -0.26, "2024-12": -1.11, "2025-03": -0.52, "2025-06": -0.34, "2025-09": -0.49, "2025-12": 0,
EPS CAGR: 116.68%
EPS Trend: -1.6%
Last SUE: -1.66
Qual. Beats: 0

Revenue

Revenue of ARCT over the last years for every Quarter: 2020-12: 2.238, 2021-03: 2.127, 2021-06: 2.001, 2021-09: 2.437, 2021-12: 5.794, 2022-03: 5.244, 2022-06: 27.093, 2022-09: 13.369, 2022-12: 160.293, 2023-03: 80.285, 2023-06: 10.519, 2023-09: 43.376, 2023-12: 25.078, 2024-03: 32.598, 2024-06: 45.976, 2024-09: 38.815, 2024-12: 21, 2025-03: 29.382, 2025-06: 24.51, 2025-09: 17.151, 2025-12: null,
Rev. CAGR: 33.56%
Rev. Trend: 36.5%
Last SUE: 0.05
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 77.1%
Value at Risk 5%th 116%
Relative Tail Risk -8.31%
Reward TTM
Sharpe Ratio -0.66
Alpha -88.94
CAGR/Max DD -0.35
Character TTM
Hurst Exponent 0.559
Beta 1.560
Beta Downside 0.656
Drawdowns 3y
Max DD 86.71%
Mean DD 43.08%
Median DD 48.06%

Description: ARCT Arcturus Therapeutics December 28, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) develops mRNA-based therapeutics and vaccines, leveraging its LUNAR lipid-nanoparticle delivery platform and STARR mRNA technology. The company’s pipeline spans rare liver and respiratory diseases (e.g., ornithine transcarbamylase deficiency and cystic fibrosis) as well as infectious disease vaccines, including COVID-19, seasonal influenza, and pandemic H5N1 strains.

Key clinical assets currently in development are ARCT-810 (LUNAR-OTC) for OTC deficiency (Phase 2) and ARCT-032 for cystic fibrosis (Phase 2). The vaccine franchise includes ARCT-2138 (LUNAR-FLU, Phase 1), ARCT-2304 (LUNAR-H5N1, Phase 1), and two COVID-19 candidates-ARCT-2301 (bivalent ancestral/Omicron, Phase 3) and ARCT-2303 (monovalent, Phase 3). The company was founded in 2013 and is headquartered in San Diego, California.

As of the latest filing (Q2 2024), ARCT reported roughly $210 million of cash and marketable securities, giving it a runway of about 12-18 months without additional financing. The broader mRNA therapeutics market is projected to grow at a CAGR of ~20 % through 2030, driven by accelerated regulatory pathways and increasing acceptance of nucleic-acid platforms. Arcturus’s recent $100 million private placement and a strategic partnership with Sanofi to co-develop mRNA vaccines underscore its ability to raise capital and access larger distribution networks.

For a deeper quantitative view of ARCT’s valuation metrics, you may find ValueRay’s analyst toolkit useful.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-66.7m TTM) > 0 and > 6% of Revenue (6% = 5.52m TTM)
FCFTA -0.21 (>2.0%) and ΔFCFTA -4.15pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 236.3% (prev 183.5%; Δ 52.85pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.21 (>3.0%) and CFO -58.3m > Net Income -66.7m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 7.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (27.2m) change vs 12m ago 0.47% (target <= -2.0% for YES)
Gross Margin 95.48% (prev 97.53%; Δ -2.05pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 28.19% (prev 38.44%; Δ -10.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -13.85 (EBITDA TTM -68.7m / Interest Expense TTM -5.19m) >= 6 (WARN >= 3)

Altman Z'' -10.85

(A) 0.77 = (Total Current Assets 249.2m - Total Current Liabilities 31.7m) / Total Assets 282.3m
(B) -1.72 = Retained Earnings (Balance) -485.5m / Total Assets 282.3m
warn (B) unusual magnitude: -1.72 — check mapping/units
(C) -0.22 = EBIT TTM -71.9m / Avg Total Assets 326.5m
(D) -8.40 = Book Value of Equity -485.5m / Total Liabilities 57.8m
Total Rating: -10.85 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 27.06

1. Piotroski 0.0pt
2. FCF Yield data missing
3. FCF Margin -63.72%
4. Debt/Equity 0.10
5. Debt/Ebitda 2.31
6. ROIC - WACC (= -40.89)%
7. RoE -28.68%
8. Rev. Trend 36.48%
9. EPS Trend -1.59%

What is the price of ARCT shares?

As of January 10, 2026, the stock is trading at USD 6.77 with a total of 444,963 shares traded.
Over the past week, the price has changed by +8.32%, over one month by -9.13%, over three months by -68.07% and over the past year by -64.27%.

Is ARCT a buy, sell or hold?

Arcturus Therapeutics has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy ARCT.
  • Strong Buy: 8
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the ARCT price?

Issuer Target Up/Down from current
Wallstreet Target Price 35.5 424.4%
Analysts Target Price 35.5 424.4%
ValueRay Target Price 5.5 -19.5%

ARCT Fundamental Data Overview January 04, 2026

P/E Forward = 2.4777
P/S = 1.8194
P/B = 0.7756
Beta = 2.101
Revenue TTM = 92.0m USD
EBIT TTM = -71.9m USD
EBITDA TTM = -68.7m USD
Long Term Debt = 26.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.55m USD (from shortTermDebt, last fiscal year)
Debt = 21.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -158.5m USD (from netDebt column, last quarter)
Enterprise Value = 19.1m USD (177.6m + Debt 21.9m - CCE 180.4m)
Interest Coverage Ratio = -13.85 (Ebit TTM -71.9m / Interest Expense TTM -5.19m)
FCF Yield = -307.3% (FCF TTM -58.6m / Enterprise Value 19.1m)
FCF Margin = -63.72% (FCF TTM -58.6m / Revenue TTM 92.0m)
Net Margin = -72.48% (Net Income TTM -66.7m / Revenue TTM 92.0m)
Gross Margin = 95.48% ((Revenue TTM 92.0m - Cost of Revenue TTM 4.16m) / Revenue TTM)
Gross Margin QoQ = 80.51% (prev 100.0%)
Tobins Q-Ratio = 0.07 (Enterprise Value 19.1m / Total Assets 282.3m)
Interest Expense / Debt = -23.74% (Interest Expense -5.19m / Debt 21.9m)
Taxrate = -0.0% (0.0 / -13.4m)
NOPAT = -71.9m (EBIT -71.9m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 7.86 (Total Current Assets 249.2m / Total Current Liabilities 31.7m)
Debt / Equity = 0.10 (Debt 21.9m / totalStockholderEquity, last quarter 224.6m)
Debt / EBITDA = 2.31 (negative EBITDA) (Net Debt -158.5m / EBITDA -68.7m)
Debt / FCF = 2.70 (negative FCF - burning cash) (Net Debt -158.5m / FCF TTM -58.6m)
Total Stockholder Equity = 232.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.43% (Net Income -66.7m / Total Assets 282.3m)
RoE = -28.68% (Net Income TTM -66.7m / Total Stockholder Equity 232.6m)
RoCE = -27.81% (EBIT -71.9m / Capital Employed (Equity 232.6m + L.T.Debt 26.0m))
RoIC = -30.42% (negative operating profit) (NOPAT -71.9m / Invested Capital 236.3m)
WACC = 10.47% (E(177.6m)/V(199.4m) * Re(11.76%) + (debt cost/tax rate unavailable))
Discount Rate = 11.76% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.05%
Fair Price DCF = unknown (Cash Flow -58.6m)
EPS Correlation: -1.59 | EPS CAGR: 116.7% | SUE: -1.66 | # QB: 0
Revenue Correlation: 36.48 | Revenue CAGR: 33.56% | SUE: 0.05 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.43 | Chg30d=+0.137 | Revisions Net=+0 | Analysts=4
EPS next Year (2026-12-31): EPS=-2.51 | Chg30d=-0.448 | Revisions Net=-1 | Growth EPS=-20.6% | Growth Revenue=-24.9%

Additional Sources for ARCT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle